2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-182080
    EVs inducer-1 710280-48-1
    EVs inducer-1 is a release inducer of immunostimulatory extracellular vesicles (EVs). EVs inducer-1 inhibits tubulin polymerization. EVs inducer-1 enhances the release of immunostimulatory EVs by antigen-presenting cells, increases the release of EV particles from dendritic cells, and elevates CD63 reporter gene activity. EVs inducer-1 inhibits the viability of proliferating cells. EVs inducer-1 is applicable for research related to immune regulation.
    EVs inducer-1
  • HY-182102
    NLRP3-IN-88 2557349-73-0 98%
    NLRP3-IN-88 (Compound 1) is an NLRP3 inhibitor. NLRP3-IN-88 inhibits IL-1β. NLRP3-IN-88 can be used in research on intestinal diseases and inflammatory diseases.
    NLRP3-IN-88
  • HY-18219R
    Walrycin B (Standard) 878419-78-4
    Walrycin B (Standard) is the analytical standard of Walrycin B. This product is intended for research and analytical applications. Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth[1][2].
    Walrycin B (Standard)
  • HY-182246
    MC2050 1301757-19-6 98%
    MC2050 is a selective PARP-1 inhibitor with an IC50 of 119 nM. MC2050 functionally inhibits PARP-1 activity, including hyperactivation induced by oxidative stress, and reduces the poly (ADP-ribosyl) ation level of histone H1. MC2050 protects neuroblastoma cells from oxidative stress-mediated cell death induced by hydrogen peroxide. MC2050 is applicable to research related to neuroblastoma and Burkitt lymphoma.
    MC2050
  • HY-182250
    BR103354 2505339-87-5 98%
    BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.
    BR103354
  • HY-182267
    Antibiofilm agent-20 98%
    Antibiofilm agent-20 is an orally active Escherichia coli biofilm inhibitor (IC50 = 5.5 μg/mL) and show low antibacterial activity (MIC >128 μg/mL). Antibiofilm agent-20 exhibits high lipophilicity and low solubility, resulting in low colon delivery rate. Antibiofilm agent-20 demonstrates anti-inflammatory and reduces IL-17 and TNF-α levels. Antibiofilm agent-20 can be used for the research of inflammatory bowel disease.
    Antibiofilm agent-20
  • HY-182268
    Antibiofilm agent-21
    Antibiofilm agent-21 is an orally active prodrug of Antibiofilm agent-20 (HY-182268) with glucuronidation. Antibiofilm agent-21 avoids absorption in the small intestine via reduced membrane permeability, improving colon delivery rate, and converts to its active form in the colon. Antibiofilm agent-21 increases colon length and reduces IL-17 and TNF-α levels in a murine DSS (HY-116282C)-induced colitis model. Antibiofilm agent-21 can be used for the research of inflammatory bowel disease.
    Antibiofilm agent-21
  • HY-182282
    PI3K/AKT-IN-6
    PI3K/AKT-IN-6 is an orally effective PI3K/AKT signaling pathway inhibitor and anti-inflammatory agent. PI3K/AKT-IN-6 inhibits the production of pro-inflammatory cytokines TNF-α and IL-6, and downregulates the expression of inflammatory mediators COX-2 and iNOS. PI3K/AKT-IN-6 improves related symptoms in colitis mice. PI3K/AKT-IN-6 can be used for the research of inflammatory diseases such as colitis.
    PI3K/AKT-IN-6
  • HY-182283
    sEH-IN-23
    sEH-IN-23 is a soluble epoxide hydrolase inhibitor with a IC50 of 0.8 nM against human sEH and 0.7 nM against murine sEH. sEH-IN-23 inhibits inflammatory factor production mediated by NF-κB activation, reactive oxygen species (ROS) generation, and the release of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. sEH-IN-23 exhibits anti-inflammatory activity in acute lung injury models. sEH-IN-23 can be used for the research of acute lung injury.
    sEH-IN-23
  • HY-182291
    COX-1/2-IN-11
    COX-1/2-IN-11 is a dual inhibitor of COX-1 and COX-2, with an IC50 of 345 nM against COX-1. COX-1/2-IN-11 can be used in the development of non-steroidal anti-inflammatory agents.
    COX-1/2-IN-11
  • HY-182293
    BTK-IN-48 3114078-55-3
    BTK-IN-48 is a BTK inhibitor with an IC50 of 1.14 μM. BTK-IN-48 inhibits recombinant BTK and c-Src, and exerts moderate inhibitory effects on LCK, BMX/ETK, FLT3 and PIM1. BTK-IN-48 can be used in the research of B-cell malignancies and autoimmune diseases.
    BTK-IN-48
  • HY-182296
    SCH 79687 224585-45-9
    SCH 79687 is an orally active histamine H3 receptor antagonist, with a Ki of 1.9 nM in rats and 13 nM in guinea pigs. SCH 79687 acts as a competitive antagonist against (R)-α-methylhistamine. SCH 79687 attenuates the inhibitory effect of (R)-α-methylhistamine-induced sympathetic hypertensive responses in guinea pigs. When used in combination with H1 antagonists, SCH 79687 inhibits Compound 48/80 (HY-115768)-induced nasal congestion in cats. SCH 79687 can be used for the research of allergic rhinitis.
    SCH 79687
  • HY-182299
    LYP-IN-5 459853-10-2
    LYP-IN-5 is a lymphoid tyrosine phosphatase (LYP) inhibitor with an IC50 value of 20.6 μM. LYP-IN-5 enhances the phosphorylation of ZAP70 and ERK1/2 following TCR stimulation, and promotes T cell activation. LYP-IN-5 can be used in the research of autoimmune diseases.
    LYP-IN-5
  • HY-182308
    LC-PDA-01
    LC-PDA-01 is a selective peroxiredoxin 1 (PRDX1) activator with an EC50 of 111.8 nM and a human KD of 123.2 nM. LC-PDA-01 inhibits the expression of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. LC-PDA-01 can be used in antioxidant/anti-inflammatory research.
    LC-PDA-01
  • HY-182335
    PF-07245303 2655556-75-3 98%
    PF-07245303 is a ITK/TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis.
    PF-07245303
  • HY-182336
    DeDPP4
    DeDPP4 is a DPP-4 PROTAC degrader. DeDPP4 induces sustained elevation of glucagon-like peptide-1 (GLP-1), enhances glucose tolerance, causes persistent reduction of blood glucose, and achieves long-term blood glucose regulation in animal models of type 2 diabetes. DeDPP4 mediates dose-dependent DPP-4 depletion in cancer cells, and also targets and degrades DPP-4 in the liver and adipose tissues of animal models with type 2 diabetes. DeDPP4 can be used for the research of type 2 diabetes and non-small cell lung cancer.
    DeDPP4
  • HY-18234B
    Leupeptin Ac-LL 24365-47-7 98%
    Leupeptin Ac-LL is a protease inhibitor from actinomycetes. Leupeptin Ac-LL has antiplasmin activity.
    Leupeptin Ac-LL
  • HY-182362
    TK-285
    TK-285 is a potent TSLP inhibitor that suppresses the production of TSLP and inhibits the expression of interleukin-33 mRNA. TK-285 exhibits a selective binding preference for the BD1 domains of BRD2, BRD3, BRD4 and BRDT. TK-285 can be used in research related to atopic dermatitis.
    TK-285
  • HY-182365
    EED-IN-4 98%
    EED-IN-4 is an orally active, EZH2-selective immunomodulator and EED-H3K27me3 inhibitor (EED, IC50=28.21 nM) with anti-inflammatory activity. In mouse models, EED-IN-4 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-4 reduces the infiltration of immune cells into the central nervous system and effectively alleviates spinal cord inflammation. EED-IN-4 shows weak inhibitory activity against hERG channels and is non-mutagenic, with no obvious toxicity observed upon long-term oral administration. EED-IN-4 can be used for the research of multiple sclerosis.
    EED-IN-4
  • HY-182366
    EED-IN-5 98%
    EED-IN-5 is an orally active, EZH2-selective trisubstituted pyridine-based EED-H3K27me3 inhibitor and immunomodulator with anti-inflammatory activity. The IC50 value of EED-IN-5 against EED is 28.21 nM. In mouse models, EED-IN-5 preferentially and persistently accumulates in lymph nodes after oral administration. By reducing the H3K27me3 level of dendritic cells and inhibiting their migration, EED-IN-5 decreases the infiltration of specific dendritic cells, macrophages and T cells into the spinal cord and brain. EED-IN-5 exhibits hERG inhibitory activity, shows negative results in the Mini-Ames test, and causes no obvious toxicity upon long-term high-dose administration. EED-IN-5 can be used for the research of multiple sclerosis.
    EED-IN-5
Cat. No. Product Name / Synonyms Application Reactivity